Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Piperazine Dihydrochloride → Irbesartan
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | Piperazine Dihydrochloride | HCID 8893 | — |
| 반응물 | Sodium Azide | HCID 33557 | — |
| 반응물 | 4'-((2-Butyl-4-oxo-1,3-diazaspiro(4.4)non-1-ene-3-yl)methyl)(1,1'-biphenyl)-2-carbonitrile | HCID 9843116 | — |
| 용매 | O-Xylene | HCID 7237 | — |
| 생성물 | Irbesartan | HCID 3749 | 96% |
반응 단계
A mixture of 2-n-butyl-3-[(2′-cyanobiphenyl-4-yl)methyl]-1,3-diazaspiro-[4,4]-non-1-en-4-one (10 g), sodium azide (7.7 g) and piperazine dihydrochloride (7.5 g) in xylene (30 ml) was refluxed for 7 hours under stirring. The reaction was cooled to room temperature and extracted with 5% NaOH solution. The pooled alkaline solution was washed with toluene or xylene (15 ml) and the aqueous phase neutralized to pH 6.5 using concentrated HCL. The resulting suspension was stirred for 3 hours at room temperature and filtered obtain irbesartan (3.6 g, 96% purity by HPLC).
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08080670B2 |
| 출처 데이터셋 | uspto-grants-2011_12 |
| ORD ID | ord-a67296b3abe540c4a17ddd7e7fd19fb6 |
| 출처 메모 | uspto-grants-2011_12 |